Zyprexa Depot: Market Potential

March 2007
Price: $2,500

Deliverable: Summary and Tabular Results of Quantitative Data

Objectives: Determine the market potential for Zyprexa Depot.  Additionally;

§         Evaluate current use of atypical and typical antipsychotics among patients with schizophrenia or bipolar disorder

§         Assess the current market for long-acting injectable antipsychotics

§         Gauge the degree to which current prescribers of oral Zyprexa will convert to prescribing Zyprexa Depot

§         Determine expected future prescribing volumes for atypical and typical antipsychotics

Products Highlighted:

§         Abilify® (aripiprazole), BMS / Otsuka America Pharmaceutical

§         Bifeprunox, Solvay Pharmaceuticals  (SVYSY, SOLbt.BR)

§         Clozaril® (clozapine), Novartis (NVS)

§         Geodon® (ziprasidone), Pfizer (PFE)

§         Invega™ (paliperidone), Janssen

§         Invega Depot™ (paliperidone palmitate), Janssen

§         Risperdal® Oral (risperidone), Janssen

§         Risperdal® Consta (risperidone), Janssen

§         Seroquel® (quetiapine), AstraZeneca (AZN)

§         Zyprexa® (olanzapine), Lilly (LLY)

§         Zyprexa Depot (olanzapine), Lilly (LLY)

§         Typical Antipsychotics, Various Manufacturers

Sample Size Screening Criteria:

§         50 respondents in total

§         Board-certified or board-eligible in psychiatry 

§         Manage at least 50 patients with schizophrenia or bipolar disorder

§         Current prescriber of Risperdal, Risperdal Consta and Zyprexa

§         2 to 30 years of practice experience

§         Spend at least 70% of professional time in clinical practice